All posts by admin

Editorial administrator

Is a fitness hero/idol important? (Editor’s Note)

Allow me to get straight to the point – a fitness hero or idol is someone who we aspire to be or has become the inspiration for the person we would like to become. Who is your fitness hero?

 

How we met

Mine came to me when I was still in primary school. At the time, I was doing the tournament rounds for tae kwon do and I got used to be the “cute” one at tournaments as well as being the youngest (usually). I also had to fight above my age level as they were the closest to my age. So imagine a short 10-year-old me having to compete in the Under-15 category (I’m still short, by the way).

The girls were big and tall, and hard to beat. It was hard for me to be able to score points although I always ended up on podium. That was a lot of work!

At the time, my parents didn’t even want me to do any martial arts. They think it would make me more masculine and learn less on how to be a lady. But I was a tomboy and I loved how I was able to focus. Heck, I wanted to be a boy!

Okay, I’m lying. It was not fun being screamed at to kick harder and faster. To do 50 – 100 push ups as fast as you can. To keep throwing punches until you feel you can’t lift your arms anymore.

But that fateful day when I was in Primary 5, I met this lady while I was being taken care of by other female competitors in their 20s. My parents never attended any tournaments, or so they said.

 

The fight

The lady in question was a brown belt, 25 years old and said she was working for Malaysian Airlines as a stewardess. She said she knew she was going to be able to participate in the tournament during the time.

She had long curly hair and wore red lipstick. “Who in their right mind would wear lipstick in a tournament?” I asked myself. She giggled a lot and kept cooing at me. I hated it.

Then she was called to fight. She turned, giggled (again) and ran with such a girlish saunter that made me wonder why she had participated in the first place. All the ladies suddenly sat upright and quiet while telling me that I had to see her fight.

I shrugged and wondered how long it would last. The moment the referee said “fight!” she hit her opponent with a spinning back hook and was K.O.-ed. She did this with a determined face and strong masculine stance.

While the referee counted down on her opponent, she switched back to that girly girl and if she could twirl her curly hair, she would. When it was pronounced that she was the winner, she ran back towards us in her light ball-on-mat run while her hair swayed side to side a la Baywatch.

 

The realization

It was during the K.O. that it occurred to me a girl can still be a girl when she’s doing martial arts. Not just martial arts – a girl can achieve anything she sets her mind to without losing her femininity. She is still my hero, especially fitness hero, because despite looking like she was so weak and dainty, she still could throw a mean kick to save her life.

I stopped resenting having guys as sparring partners. Instead I look at them as challenges. I learnt to overcome obstacles from this. I learnt that I had to be fitter than them to beat them.

I also learnt that being fit does not necessarily equate to huge bulging muscles.

I never knew her name but lady, you’re the inspiration for everything I have done, achieved and overcome. That one K.O. was more than enough to tell me I’m good. I’m ok.

Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia

BEIJING, July 19, 2018 /PRNewswire/ — Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced the grand opening of Anderson Biotech Company Limited and Royal OncoCare Hospitality as two wholly owned subsidiaries of Yisheng Biopharma in Cambodia. The two divisions represent the first expansion of Yisheng Biopharma business and product sales operations into an ASEAN member country.

“The opening of these two divisions is an important milestone in company history,” commented Zhang Yi, Founder and Chairman of Yisheng Biopharma. “Our product YivykaTM is approved in Cambodia for the treatment of advanced solid tumors, including lung, breast, liver, colorectal and stomach cancers. We are pleased to be in a position to expand access to the benefits that this product will bring to cancer patients and are grateful for the support we have received from the Ministry of Health of the Kingdom of Cambodia.”

“ASEAN countries have witnessed a significant economic boom over the last decade and represent one of the fastest growing markets for the biopharmaceutical industry,” added David Shao, Ph.D., President and CEO of Yisheng Biopharma. “With a population of over 600 million under-served individuals in these countries, we are committed to expanding and deepening our presence in this region of southeast Asia. We are conducting drug development in this region, with programs in immuno-oncology, rabies and hepatitis B infection, and are well positioned to introduce a series of innovative products into this region.”

YivykaTM is an innovative immuno-oncology drug recently granted a drug registration license by the Ministry of Health of the Kingdom of Cambodia. YivykaTM is the first biological product introduced into the Cambodia market by Yisheng Biopharma. 

About Yisheng Biopharma Co., Ltd.

Yisheng Biopharma is a global biopharmaceutical company discovering, developing and commercializing innovative immunological biologics. With approximately 700 employees worldwide and operations in China, the United States, Singapore and certain Southeast Asian countries. 

www.yishengbio.com

View original content:http://www.prnewswire.com/news-releases/yisheng-biopharma-announces-opening-of-new-business-divisions-in-cambodia-expanding-presence-within-southeast-asia-300683333.html

Source: Yisheng Biopharma Co., Ltd.

University of Louisville Hospital Selects Orion Health to Support Interoperability Initiatives

Academic Research Hospital Goes Live with Cloud-Based Offering Rhapsody as a Service

BOSTON, July 19, 2018 /PRNewswire/ — Orion Health, a leading provider of interoperability, population health management and precision medicine solutions, today announced that University of Louisville Hospital (UofL Hospital) has gone live with its Rhapsody as a Service (RaaS) cloud-based integration engine. RaaS, powered by Amazon Web Services (AWS), provides UofL Hospital with rapid and scalable interoperability capabilities, connecting disparate technologies within the healthcare system and moving them to the cloud.

UofL Hospital, a longstanding Rhapsody Integration Engine customer, needed a new interoperability solution that would allow the health system to immediately build its own interfaces to support a variety of organizational initiatives, without any unscheduled downtime. UofL Hospital selected RaaS as it wanted an agile, cloud-based solution that it could easily and securely migrate its previous interface engine onto.

“After a thorough search of all available interoperability solutions in the market, it was clear to us that Orion Health’s RaaS solution was the only option that would meet our entire list of criteria,” said Doug Jones, Chief Information Officer, University of Louisville Hospital. “Working in a cloud environment is already adding expansive value to our IT systems.”

Since deploying RaaS in early 2018, UofL Hospital is already sending over 2.5 million messages a day and has saved countless hours in deploying software and maintaining systems. Since go-live, the health system has realized over 99% uptime, which is critical to meeting the organization’s interoperability and data management initiatives.

“We are seeing an uptick in demand for our best-in-class cloud-based integration engine since we released it earlier this year, which is mainly due to the alignment between the benefits the solution offers and the top priorities of health systems today — including an increased focus on reducing risk and increasing the scalability of mission-critical technology,” said Drew Ivan, Chief Technology Officer, Orion Health. “University of Louisville Hospital is a true innovator when it comes to both technology and patient care, and we are excited to partner with them to help them realize the full benefits of RaaS. It is imperative that a large system like Louisville has 24/7 access to accurate data across its enterprise, and we are proud that our intelligent data integration tools help support its ultimate mission to provide superior patient care.”

For years, the Rhapsody Integration Engine has provided rapid and scalable interoperability to more than 640 healthcare systems in 36 countries. The new RaaS offering from Orion Health offers the same powerful features and benefits to healthcare organizations working in a cloud environment. RaaS uses AWS to scale storage capacity and computing power so that the customer only uses, and pays for, what it needs. The solution also provides off-the-shelf compliance that adheres to the appropriate healthcare guidelines. This cloud-based solution aggregates and stores data in offsite and multiple locations while providing organizations with secure and reliable access to its data.

About University of Louisville Hospital

Incorporated in 1995 and based in Louisville, Ky., University Medical Center Inc. operates as a non-profit affiliate of the University of Louisville. Under the leadership of President and CEO Ken Marshall, UMC provides management and oversight of the UofL Health Sciences Center’s primary adult teaching hospital and cancer center. University of Louisville Hospital traces its origins to 1817 and today is a 404-bed facility with the region’s only adult Level 1 trauma center, Kentucky’s first certified stroke center and first hospital-based telemedicine network. Aligned with the hospital, the James Graham Brown Cancer Center offers the area’s most advanced cancer treatment with specialists and researchers working in multidisciplinary teams and is home to the first nationally accredited breast center in Kentucky and the first nationally accredited radiation oncology program in Louisville. More than 500 physicians and 2,300 nurses and other staff provide care at the two facilities, located adjacent to one another in the heart of Louisville’s medical center on Jackson Street between East Chestnut and East Muhammad Ali. To learn more, visit the UofL Hospital and Brown Cancer Center websites.

About Orion Health

Orion Health (NZX:OHE) is a global health technology company that provides solutions which enable healthcare to more than 100 million patients globally. Built on an open platform, Orion Health is a leading provider of interoperability, population health management and precision medicine solutions. The global company is committed to continual innovation, investing substantially in research and development to cement its position at the forefront of precision medicine. For more information visit www.orionhealth.com.

View original content:http://www.prnewswire.com/news-releases/university-of-louisville-hospital-selects-orion-health-to-support-interoperability-initiatives-300683417.html

LKKHPG Honored with Outstanding CSR Award for Seven Consecutive Years

HONG KONG, July 20, 2018 /PRNewswire/ — On July 18, 2018, the seventh Outstanding CSR Award Presentation Ceremony hosted by The Mirror was held in Hong Kong. The ceremony gathered more than 500 government officials, entrepreneurs, professors and scholars from mainland China, Hong Kong, Macao and Taiwan. Vice chairman of the National Committee of the Chinese People’s Political Consultative Conference, Mr. C.Y. Leung spoke at the ceremony. LKK Health Products Group (LKKHPG) won the Outstanding CSR Award for the seventh consecutive year, and Infinitus (Hong Kong) Company Ltd., a member of LKKHPG, won the award for the first time.

The panel members gave in-depth analysis and professional assessments on various dimensions including employee care, commitment to shareholders, environment protection and social engagement. The final award recipients included AIA, Watsons, and other well-known enterprises.


Si Li Ji Ren Education Dream Support Program helps poverty-stricken students to pursue their career dreams

In 2017, Infinitus (China) Company Ltd., also a member of LKKHPG, actively responded to the United Nations (UN) initiatives. It integrated the UN Sustainable Development Goals (SDGs) with its own business practices, and formulated four action plans on Health, People, Earth and Society, thereby launching a new phase of CSR.

LKKHPG said: “Receiving the award for the seventh consecutive year is recognition for our CSR, which will motivate us in our future endeavors. We will continue carrying out the responsible practices in the four fields of Health, People, Earth and Society, helping more people achieve health and happiness, and realizing sustainable development goals for society.”

Over the past years, with the two platforms of Si Li Ji Ren Foundation and Infinitus Volunteers Association, LKKHPG has developed a number of CSR programs and provided volunteer service such as the Si Li Ji Ren Education Dream Support Program and the Infinitus Happy Football Program. So far, LKKHPG has held more than 200 activities and provided over 25,000 hours of volunteer service with over 6,200 volunteers, and has donated money and supplies worth over RMB 200 million.

Photo – https://photos.prnasia.com/prnh/20180720/2192226-1

Source: Infinitus (China) Company Ltd.

Masayoshi Son: Ping An Good Doctor’s AI Healthcare Technology is the Most Advanced in the World

HONG KONG, July 20, 2018 /PRNewswire/ — China’s leading one-stop healthcare ecosystem platform, Ping An Healthcare and Technology Company Limited (“Ping An Good Doctor“, the “Company”, stock code: 1833.HK), Didi Chuxing, ZhongAn Insurance and other outstanding internet technology companies were invited to attend the Softbank World 2018 conference in Tokyo on 19 July. During the conference, Mr. Masayoshi Son, Chief Executive of SoftBank Group, told the audience that, “Ping An Good Doctor’s AI healthcare technology is the most advanced in the world.”


Mr. Wang Tao, Chairman and CEO of Ping An Good Doctor, was invited to attend the Softbank World 2018 Conference and deliver a speech

Mr. Son has respected the work of Ping An Good Doctor for a long time. On 4 May, Ping An Good Doctor was listed in the HKEx, becoming the first listed HealthTech company in the world. As far back as the end of 2017, one month before Ping An Good Doctor submitted its listing application to the HKEx, Mr. Son had already invested USD400 million in Ping An Good Doctor through SoftBank Vision Fund.

Mr. Wang Tao, Chairman and CEO of Ping An Good Doctor, participated in the Softbank World 2018 conference as a special guest and talked about the achievements of the Company in the AI family doctor area.

According to Mr. Tao, the uneven distribution of medical resources, particularly quality medical resources, is an international issue. The lack of quality primary care and the scarcity and uneven distribution of quality medical resources have long been the source of structural weaknesses in the Chinese healthcare services industry. It is very common for patients to wait a few hours in order to receive a consultation that lasts a few minutes, and there is a lack of family doctors in China. As such, Ping An Good Doctor has established a one-stop healthcare ecosystem platform with its unique model of “AI doctor + Full-time medical team + External medical resources” in order to address the issue and tap into this enormous market.

Mr. Tao said, Ping An Good Doctor has established a full-time medical team of around 1,000 professionals and they cover 20 specialties at the “internet hospital”. Leveraging on its self-owned medical team and the standardized consulting process, Ping An Good Doctor is able to provide a quality and reliable user experience. According to the survey, the satisfaction of Ping An Good Doctor’s online medical consultation service reached 97%.

In the application of AI technology, Mr. Tao said that the AI doctor, which is exclusively run by Ping An Good Doctor, interacts with the users and guides them to accurately describe their symptoms, thus forming a structured medical record for each user. The AI doctor then provides a smart diagnosis plan based on the big medical treatment data of millions of records for the doctor’s reference. It can also offer a smart prescription after the doctor’s consultation and diagnosis.

It is understood that the AI doctor, enabled by smart voice, semantics and other technologies can increase the efficiency of doctors’ consultation times by more than five times. In 2017, Ping An Good Doctor provided more than 370,000 medical consultations per day. Taking advantage of its dedicated medical team and the AI technology, Ping An Good Doctor provides the users with online consultations, either by text and photos or by video chat, 24 hours a day, 7 days a week, and accurately identifies the users’ health needs.

Mr. Tao said that Ping An Good Doctor is accelerating to develop a comprehensive healthcare ecosystem. At present, Ping An Good Doctor has established a nationwide network of healthcare service providers, including approximately 40,000 external doctors, over 3,000 hospitals, as well as over 2,000 health service organizations. Meanwhile, Ping An Good Doctor has also cooperated with more than 10,000 offline pharmacies to launch the “one-hour drug delivery” service in dozens of cities in China.

In addition to exploring the application areas of AI doctor in China, Ping An Good Doctor is also actively looking to global markets to integrate medical service resources. Ping An Good Doctor cooperates with dozens of medical institutions in Japan. On a global scale, Ping An Good Doctor has built a medical service network to cooperate with hundreds of well-known hospitals covering nearly 10 countries and regions including the United States, Japan, South Korea, Switzerland and Singapore.

“As an internet healthcare company, the vision of Ping An Good Doctor is to help every family to have a family doctor, and every user to have an electronic health record and a health management plan”, Mr. Tao said.

About Ping An Healthcare and Technology Company Limited

Ping An Healthcare and Technology Company Limited (the “Company”) is a pioneer in the PRC Internet healthcare market and operate the largest Internet healthcare platform in terms of average MAUs and daily average online consultations in 2016.

Through the company’s mobile platform launched in April 2015, the company offers online medical and wellness services, such as family doctor services, consumer healthcare services, health mall as well as health management and wellness interaction. As of December 31, 2017, there were 192.8 million registered users, who benefit from access to quality healthcare services at their fingertips. In 2015, 2016 and 2017, average MAUs, calculated as the average of MAUs for each calendar month, reached 5.6 million, 21.8 million and 32.9 million across its platform, respectively.

The mission of the company is to build the largest healthcare ecosystem in the world and promote healthy living empowered by technology. Ping An Healthcare and Technology Company Limited’s family doctor services, mobile platform and service provider network make it a vital online portal and a vibrant healthcare ecosystem. Taken together, the breadth and depth of company’s user base and user engagement, technological capabilities and network of service providers form a substantial entry barrier for competitors.

Photo – https://photos.prnasia.com/prnh/20180720/2192193-1

ConferenceSeries offers One-of-A-Kind Experience with On-Site and Online Scientific Conferences

Event organizer bringing its 10 years of healthcare communication expertise and deep knowledge of research to the scientific community

LONDON, July 19, 2018 /PRNewswire/ — ConferenceSeries is a medical and life sciences event organiser engaged in ‘Healthcare Communication’ for over a decade through a series of scientific conferences across Europe, Asia and America. The uniqueness of the ConferenceSeries lies in its ability to collaborate with renowned scientific agencies within America and abroad and form ties with scientific societies to organize Medical Conferences, Pharmaceutical Conferences, Life Science Conferences and Engineering Conferences.

Established with a view to organize independent medical meetings, ConferenceSeries serves a vast business and academic clientele base that includes organizations indulged in medical science  research, clinical practices and the pharmaceutical industry. ConferenceSeries could completely transform the traditional role of the scientific conference organizer that allowed interaction among the participants who are physically attending it. Effective from 2019 ConferenceSeries also offers Online scientific events in association with its partnered companies on 50+ different disciplines, said Dr. Srinubabu Gedela, CEO, Omics International.

All major meetings of ConferenceSeries are accredited with Continued Professional Education(CPD), Continued Education (CE), and Continued Medical Education (CME) Credits. ConferenceSeries takes the stand of a legitimate body, vested with the responsibility of assessing the scientific content and assures its quality as per the accepted standards. ConferenceSeries encourages the early stage academicians and researchers to be part of the Young Research Forum, Best Poster Competition and E-Poster to collaborate for effective partnering, interaction with fellow young researchers and senior researchers and guidance on career prospects, fostering transcontinental cooperation, mutual agreement and engagement among young researchers. Its events help to gain visibility in the global context.

ConferenceSeries is a crucial player in organizing 2000+ International Conferences annually in over twenty European Countries (UK, Germany, Spain, Italy, Ireland, Netherlands, Belgium, France, Austria, Portugal, Czech Republic etc.) in some of the top most conference destinations (London, Rome, Berlin, Madrid, Barcelona, Amsterdam, Brussels, Paris, Vienna, Lisbon, Prague, etc.). ConferenceSeries is partnered with Omics International to conduct conferences and publish proceedings. It focuses on a wide array of subjects such as: Agriculture, Biochemistry, Cardiology, Chemical Engineering, Chemistry, Dentistry, Diabetes, Engineering, Environmental Sciences, Food, Gastroenterology, Genetics, Geology-Earth Science, Healthcare, Immunology, Infectious Diseases, Materials Science, Microbiology, Nanotechnology, Nephrology, Neuroscience, Nursing, Nutrition, Oncology, Ophthalmology, Pediatrics, Pharmaceutical Sciences, Surgery, Vaccines and Veterinary among many others.

Contact :+1 6508894686 email: contact@conferenceseries.com

Shedding New Light on Pediatric Research by Integrating the Healthcare Providers of the Globe

Pediatric ConferenceSeries offers On-Site and Online medical Conferences effective from 2019

LONDON, July 20, 2018 /PRNewswire/ — ConferenceSeries Pediatric Conferences reinforce the spirit of healthy neonates to build physically and mentally fit societies to excel in socioeconomic and cultural progress.

Children are prone to succumb to seasonal as well as chronic diseases that are inherited diseases. Temporary and sudden illness due to the atmospheric changes affect children causing cough, cold, flu, diarrhea, gastroenteritis, fever and respiratory infections. The above mentioned ailments occur due to air borne, water borne and food related infections causing extreme inconvenience to the children, causing anemia, sleeplessness, indigestion, including mortality and morbidity if not responded well in time. Children are also increasingly affected by Diabetes, hypertension, obesity, and inherited cardiac and mental disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety and depression. Pediatric health disorders are posing enormous economic burden to the society apart from affecting the demographic and sociographic equations. These conferences focus on the latest and exciting innovations in Pediatrics such as pediatric nutrition, pediatric immunology, pediatric hematology and oncology, pediatric allergy, pediatric cardiology, pediatric neurology, pediatric psychology, pediatric emergencies etc.  Effective from 2019 ConferenceSeries also offers Online scientific events in association with its partnered companies on different medical, healthcare and other scientific disciplines, said Dr. Srinubabu GedelaCEO, Omics International.

Global burden of pediatric mortality is increasing drastically every year. According to WHO estimations, 8.8 million children below 5 years of age are dying each year. 3.8 million Children are dying within 30 days of birth, accounting for 36% of neonatal deaths due to infectious diseases. The global market for Pediatric healthcare was estimated at $80.7 billion in 2013. This has reached nearly $83.6 billion in 2014 and it is expected to reach $100.7 billion by 2019. According to the recent analysts forecast the global pediatric medicines market to grow at a CAGR of 4.97% during the period 2018-2021.

Conference series major CME Pediatrics Meetings includes Clinical Pediatrics, Pediatric Cardiology, Pediatric Surgery, Pediatric Nutrition, Pediatric Primary Care, Pediatric Neurology and Neonatology. ConferenceSeries partnered with Omics Group for proceedings publication. With 3000+ annual international conferences, Conference Series aims to encourage novel research on advanced diagnosis, treatment and rehabilitation through a series of worldwide conferences.

Contact
Pediatrics Conferences
contact@conferenceseries.com + 1-888-843-8169

Logo – https://mma.prnewswire.com/media/554693/Conference_Series_Logo.jpg

AWAK Technologies Strengthens Presence in Singapore with New Headquarters

SINGAPORE, July 16, 2018 /PRNewswire/ — AWAK Technologies (AWAK), a pioneering medical technology company focused on dialysis using regeneration technology for end-stage renal disease, today announced a move to its new headquarters, strengthening its presence in Singapore to support growth over the next few years.


The new AWAK headquarter will house 16 employees in research, regulatory and business development functions.

The new 6,000 square foot office in Tuas, Singapore, houses 16 employees in research, regulatory and business development functions. AWAK will also have a fully-equipped chemistry lab, engineering lab and a clean room manufacturing facility to support the company’s research, development, manufacturing and commercial activities.

AWAK’s move to its new headquarters follows the appointment of AWAK’s new management team
late-2017. Led by Chief Executive Officer Suresh Venkataraya, the management team consists of: 

  • Mandar Gori, Director of Marketing and Business Development
  • Daniel Tan, Director of Program Management and Operations
  • Joel Preetham Fernandes, Director of R&D and Quality
  • Carol Lim, Head of Finance and HR

The new management team has a combined global commercial experience of close to 50 years in medical devices covering R&D, Finance, QA/RA, Supply Chain, Manufacturing, Sales, Marketing and FDA and CE approvals, and underscores AWAK’s vision in bringing its patented sorbent technology that enables the development of ultra-portable peritoneal and haemodialysis machines to market globally. By 2023, the global dialysis market is projected to grow to US$124 billion1.

AWAK has also recently formed a Technical Advisory Committee, which will provide scientific guidance and advice on product development, comprised of senior advisors who are scientific experts in biochemistry, biopharmaceuticals and commercialisation of dialysis technologies. In addition, the Medical Advisory Board includes experts such as Dr Gordon Ku (Founder and Chairman of Kidney Dialysis Foundation, Singapore) and Prof A. Vathsala (Co-Director of the National University Centre for Organ Transplantation at the National University Health System, Singapore).

Suresh Venkataraya, Chief Executive Officer, AWAK, said: “We have made significant progress in recent years, including securing financing from Southeast Asia’s largest medtech company, Accuron MedTech, which will accelerate the research and development of our product. We expect to complete our first-in-human trial this quarter, a significant milestone for AWAK. I am excited about AWAK’s next phase of growth as we look to bring our revolutionary technology to markets globally and change the lives of end-stage renal disease patients worldwide.”

Media contacts

Emma Thompson/Stephanie Tan
Spurwing Communications
+65 6340 7287
awak@spurwingcomms.com     

About End-Stage Renal Disease

The End stage Renal Disease (ESRD) is the fifth stage of Chronic Kidney Disease (CKD) that affects the functioning of kidneys, leading to accumulation of excess fluid and toxic wastes in the blood. People with ESRD undergo either renal transplantation or dialysis. Since renal transplantation is highly dependent on patient’s health and age, dialysis scores over as the primary treatment. It was estimated as of 2011, there were 2.7 million ESRD patients of whom 2.1 million were on dialysis. Of these 2.1 million, 10.8% of the patients are on peritoneal dialysis (PD) and the remaining 89.2% are on hemodialysis (HD)2.

Dialysis treatment can be performed either at home, in a dialysis centre or at a hospital. In hemodialysis, blood is drawn out of the patient’s body into a synthetic filter called dialyser. In the dialyser, there are two spaces separated by a membrane, with blood passing on one side and dialysis fluid on the other side. Waste products and excess water passes from the blood through the membrane into the fluid through diffusion process. The fluid containing the waste products is then discarded while the clean blood is returned back to the patient’s body. In peritoneal dialysis, the lining of the abdominal cavity acts like the external filter to cleanse the blood. Dialysis fluid is introduced into the abdominal cavity through a permanent tube. The fluid remains in the abdominal for a certain period of time before it is drained and discarded.

About AWAK Technologies

AWAK Technologies Pte Ltd. is a pioneering, patient-centric medical technology company with a mission to enhance the lives of dialysis patients and their caregivers by providing solutions to deliver better outcomes and improve their quality of life.

Headquartered in Singapore with an office in Burbank, California, USA, the company is dedicated to the research, development and marketing of novel, sorbent-based kidney dialysis machine for the treatment of patients with end-stage renal disease. For more information, please visit: www.awak.com

1 KBV Research. (2017). Global Dialysis Market.

2 Damien, P., Lanham, H. J., Parthasarathy, M., & Shah, N. L. (2016). Assessing key cost drivers associated with caring for chronic kidney disease patients. BMC Health Services Research, 16, 690. http://doi.org/10.1186/s12913-016-1922-4

Photo – https://photos.prnasia.com/prnh/20180716/2187539-1

SMA and RMA launched the first medical tourism product that will allow Chinese patients to access via UnionPay online payment system in North America.

NEW YORK, July 19, 2018 /PRNewswire/ — To meet the increasing demand for healthier next generations from Chinese families, Supreme Medicine Advisors (SMA) and Reproductive Medicine Associates of New York (RMA) spent the last 12 months developing a program that is customized to meet Chinese families’ needs for reproductive medicine.  SMA is the authorized partner to represent RMA’s brand in China.  The alliance designed the “Assist you to conceive” series to better serve Chinese families with the most advanced medical technology and comprehensive and professional concierge services with a one-stop solution.  They parties are committed to education and have produced a weekly interview with RMA specialists to help more families in China to access accurate and objective information prior to traveling to the United States.


Peiwen Shih, Founder and President of SMA (left) and Dr. Alan Copperman, Founder and Managing Partner of RMA

Peiwen Shih, Founder of SMA said, “We plan to utilize the extensive medical resources we cultivated in U.S. to help more Chinese families accessing quality medical services.”

Chinese clients can log onto RMA’s web site to access “Assist you to conceive” services by using their UnionPay debit card or credit cards online and pay the medical institution directly with simple steps.  There are no fees, and the online transaction and the client info are secured by UnionPay.

There are over 40 million families in China who might need infertility treatment (about 1 in every 8 couples), based on the latest survey from China.  There are also increasing numbers of high risk pregnancies and genetic conditions based on the women’s age, since China began to allow families to have asecond child.

Dr. Alan Copperman, Co-Founder and Managing Director of RMA of New York, is thrilled about the opportunity to assist more Chinese families. “For more than 17 years, we have helped patients from over 150 countries meet their family building dreams.  Our success is based on utilizing the most advanced medical technology and practicing comprehensive care so that we meet each family’s needs.  With the collaboration with SMA, Chinese families will be able to access the world-class assisted reproductive technology with convenience and with language and cultural support throughout the process.”

About Supreme Medicine Advisors
Headquartered in New York, U.S., SMA was established to build a professional platform that will allow patients, medical institutions and health management companies in China to access quality medical services and advanced medical technology in U.S.  SMA has cultivated an extensive medical network to develop and design packaged services tailored for Chinese patients.  The one-stop solution to include medical and concierge services were created to revolutionize the traditional medical concierge industry. SMA’s commitment to provide reliable and professional educational info also set itself apart from the rest of the competition.

About Reproductive Medicine Associates of New York
Reproductive Medicine Associates of New York (RMA of New York) is widely recognized as a global leader in state-of-the-art reproductive medicine. Led by an integrated team of doctors and scientists with extensive reproductive endocrinology, fertility and urology experience and training, RMA of New York consistently reports IVF success rates to the Society for Assisted Reproductive Technology (SART) and the Center for Disease Control and Prevention (CDC) and is internationally recognized for achieving high success rates in the treatment of infertility. Headquartered in midtown Manhattan, RMA of New York has six patient care facilities throughout New York, including three facilities in Manhattan, as well as in Brooklyn, Long Island, Westchester, and abroad in Mexico City. For more information, please visit www.rmany.com.

Photo – https://mma.prnewswire.com/media/719767/SMA.jpg
Photo – https://mma.prnewswire.com/media/720143/SMA_Wechat_QR_code.jpg   

China YCT International Group Files Registration Statement on Form S-1 and Application for NASDAQ Capital Market Listing

JINING, China, July 17, 2018 /PRNewswire/ — China YCT International Group, Inc. (OTCQB: CYIG) (the “Company”) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed public offering of shares of its common stock, par value $0.001 per share, for gross proceeds of $7,500,000, excluding the proceeds from the sale of additional shares of common stock to cover over-allotments, if any. The number of shares to be offered and the price range for the proposed offering have not yet been determined. China YCT International Group, Inc. has applied to list its common stock on The Nasdaq Capital Market.

Maxim Group LLC will act as the sole book-running manager for the proposed offering.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The proposed offering will be made only by means of a prospectus

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About China YCT International Group, Inc.

Based in Sishui County, Shandong Province and founded in January 1989, China YCT International Group, Inc., through its subsidiaries, engages in the business of (i) distributing health care supplement products manufactured by Shandong Yongchuntang Group Co., Ltd. in the PRC, (ii) developing, manufacturing, and selling Huoliyuan capsules, a prescription medicine, (iii) developing acer truncatum bunge planting bases, and manufacturing and selling acer truncatum bunge seed oil in the PRC. Acer truncatum bunge plants are a species of maple tree. For more information about the Company, please visit http://zgyct.yongchuntang.com.

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

At the Company:

Zecheng Shao, Vice President
Phone: +86-156-5377-2006
Email: zc_shao@126.com

Investor Relations:

Tony Tian, CFA
Weitian Group LLC
Phone: +1-732-910-9692
Email: ttian@weitianco.com

View original content:http://www.prnewswire.com/news-releases/china-yct-international-group-files-registration-statement-on-form-s-1-and-application-for-nasdaq-capital-market-listing-300682016.html

Source: China YCT International Group, Inc.